Pfizer 2012 Annual Report Download - page 21

Download and view the complete annual report

Please find page 21 of the 2012 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 121

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121

Financial Review
Pfizer Inc. and Subsidiary Companies
20
2012 Financial Report
Other Product Revenues
2012 v. 2011
Animal Health Operating Segment
• Animal Health unit revenues increased 3% in 2012, compared to 2011, reflecting higher operational revenues of 6%, partially offset by
the unfavorable impact of foreign exchange of 3%. Operational revenues from Animal Health products were favorably impacted by the
solid performance in both the livestock and companion animal portfolios.
Consumer Healthcare Operating Segment
• Consumer Healthcare unit revenues increased 6% in 2012, compared to 2011, reflecting higher operational revenues of 8%, partially
offset by the unfavorable impact of foreign exchange of 2%. The operational revenue increase was primarily due to the addition of
products from the acquisitions of the consumer healthcare business of Ferrosan in December 2011 and Alacer Corp. in February 2012.
2011 v. 2010
Animal Health Operating Segment
• Animal Health unit revenues increased 17% in 2011, compared to 2010, reflecting higher operational revenues of 14% and the favorable
impact of foreign exchange of 3%. Operational revenues from Animal Health products were favorably impacted by approximately $329
million, or 9%, due to the addition of revenues from legacy King animal health products. Legacy Pfizer products grew 7% primarily driven
by improving market conditions and resulting increased demand for products across the livestock business, as well as deeper market
penetration in emerging markets. This was partially offset by the adverse impact of required product divestitures in 2010 related to the
acquisition of Wyeth.
Consumer Healthcare Operating Segment
• Consumer Healthcare unit revenues increased 10% in 2011, compared to 2010, reflecting higher operational revenues of 8% and the
favorable impact of foreign exchange of 2%. The operational revenue increase in 2011 was primarily driven by increased sales of core
brands including Advil, Caltrate and Robitussin, as well as the temporary voluntary withdrawal of Centrum in Europe in the third quarter of
2010, which had an adverse impact on 2010 revenues.
Revenues—Major Biopharmaceutical Products
The following table provides revenue information for several of our major biopharmaceutical products:
(MILLIONS OF DOLLARS)
PRIMARY INDICATIONS
Year Ended December 31, % Change
PRODUCT 2012 2011 2010 12/11 11/10
Lyrica Epilepsy, post-herpetic neuralgia
and diabetic peripheral neuropathy,
fibromyalgia, neuropathic pain due
to spinal cord injury
$4,158 $3,693 $3,063 13 21
Lipitor Reduction of LDL cholesterol 3,948 9,577 10,733 (59)(11)
Enbrel (Outside the U.S.
and Canada)
Rheumatoid, juvenile rheumatoid
and psoriatic arthritis, plaque
psoriasis and ankylosing
spondylitis
3,737 3,666 3,274 212
Prevnar 13/Prevenar 13 Vaccine for prevention of
pneumococcal disease
3,718 3,657 2,416 251
Celebrex Arthritis pain and inflammation,
acute pain
2,719 2,523 2,374 86
Viagra Erectile dysfunction 2,051 1,981 1,928 43
Norvasc Hypertension 1,349 1,445 1,506 (7) (4)
Zyvox Bacterial infections 1,345 1,283 1,176 59
Sutent Advanced and/or metastatic renal
cell carcinoma (mRCC), refractory
gastrointestinal stromal tumors
(GIST) and advanced pancreatic
neuroendocrine tumor
1,236 1,187 1,066 411
Premarin family Menopause 1,073 1,013 1,040 6(3)
Genotropin Replacement of human growth
hormone
832 889 885 (6) —
Xalatan/Xalacom Glaucoma and ocular hypertension 806 1,250 1,749 (36)(29)
BeneFIX Hemophilia 775 693 643 12 8
Detrol/Detrol LA Overactive bladder 761 883 1,013 (14)(13)
Vfend Fungal infections 754 747 825 1(9)